Investigating how T cells and B cells work together after vaccination
CD8 T cell and B cell collaboration following subunit vaccination
This study is looking at how two important types of immune cells, CD8 T cells and B cells, work together after getting a special vaccine to help boost our body's defense against diseases like cancer, with the hope of creating better vaccines for illnesses that don’t have good options right now.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Colorado Denver NIH-funded |
| Lab location | 1 site (Aurora, UNITED STATES) |
| Project ID | NIH-10662244 on NIH RePORTER |
What this research studies
This research focuses on understanding the collaboration between CD8 T cells and B cells following vaccination with a protein subunit antigen. By using a combined-adjuvant subunit vaccine, the study aims to enhance immune responses against various pathogens, including cancer. The researchers will explore the mechanisms that control the effectiveness of this vaccine approach, which could lead to the development of more effective vaccines for diseases that currently lack viable vaccination options. Patients may benefit from insights gained into how to improve immune responses through vaccination.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals who are at risk for diseases that could be prevented or treated with improved vaccines, such as cancer patients or those with chronic infections.
Not a fit: Patients who are not at risk for the diseases being targeted by the vaccine, or those who have already received effective vaccinations, may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to the development of more effective vaccines that provide better protection against diseases like cancer and infectious diseases.
How similar studies have performed: Other research has shown promise in enhancing immune responses through innovative vaccine approaches, suggesting that this line of investigation could lead to significant advancements.
Where this research is happening
Aurora, UNITED STATES
- University of Colorado Denver — Aurora, United States (Active)
Researchers
- Principal investigator: Kedl, Ross M — University of Colorado Denver
- Study coordinator: Kedl, Ross M
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.